Empagliflozin mitigates metabolic dysfunction‐associated steatotic liver disease by reducing de novo lipogenesis in a mouse model of lipoatrophic diabetes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Empagliflozin mitigates metabolic dysfunction‐associated steatotic liver disease by reducing de novo lipogenesis in a mouse model of lipoatrophic diabetes

Published:2024-05-03 Issue:8 Volume:26 Page:3466-3470
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Smati Sarra¹,Sotin Thibaud¹,Deniel Perrine¹,Ducheix Simon¹,Joubert Michael²,Arnaud Lucie¹,Hadjadj Samy¹,Cariou Bertrand¹^ORCID,Le May Cédric¹,Prieur Xavier¹^ORCID

Affiliation:

1. l'Institut du Thorax, INSERM, CNRS, UNIV Nantes, CHU Nantes Nantes France

2. EA4650 – Unicaen – GIP Cyceron – Caen Caen France

Funder

Fondation pour la Recherche Médicale

Publisher

Wiley

Reference14 articles.

1. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

2. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes

3. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options

4. Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial

5. Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP